Sugi Predict

Sugi Predict / Compounds / SCHEMBL4238182

SCHEMBL4238182

SCHEMBL4238182

Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NCC(CNC(C)(C)C)C3)ccc1=O

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK13 O15264 4/20 0.78
▸ MAPK11 Q15759 4/20 0.78
▸ CYP2C9 P11712 1/20 0.78
▸ MAPK12 P53778 3/20 0.36
▸ MAPK14 Q16539 3/20 0.36
▸ FGFR1 P11362 1/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ CSNK1D P48730 1/20 0.30
▸ CSNK1E P49674 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29593689 1.00 MAPK13 (0.78) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL29594201 0.91 MAPK13 (0.82) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL4241286 0.91 MAPK13 (0.82) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL4237010 0.90 MAPK11 (0.64) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL4240223 0.90 MAPK11 (0.64) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL29594974 0.90 MAPK11 (0.64) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL29593312 0.90 MAPK11 (0.64) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL29593646 0.88 MAPK13 (0.61) MAPK13MAPK11CYP2C9MAPK12MAPK14
SCHEMBL4244865 0.88 MAPK13 (0.61) MAPK13MAPK11CYP2C9MAPK12MAPK14
As1940477 SCHEMBL13928941 0.88 MAPK13 (1.00) MAPK13MAPK11CYP2C9MAPK12MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159212-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. (US) 2023-04-05 — — EP disclosed
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD FULCRUM THERAPEUTICS INC (US) 2022-05-05 — — US disclosed
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2022-04-05 — — US disclosed
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC (JP) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133704-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK13 303/4885MAPK11 857/4885CYP2C9 4736/4885
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN HRH2, OPRD1, HRH4 MAPK13 1439/4885MAPK11 1195/4885CYP2C9 359/4885
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 MAPK13 303/4885MAPK11 857/4885CYP2C9 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.